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Eruptive keloids are rarely described in the
literature and are typically reported in association
with a systemic disease. Because reports of eruptive
keloids are sparse, the pathophysiology of eruptive
keloids remains to be clearly explained. We report a
case of a 77-year-old woman who had extensive
eruptive keloids while taking letrozole for hormone
receptorepositive infiltrating ductal carcinoma. No
further progression of lesions was noted on
discontinuation of the medication. Letrozole is an
aromatase inhibitor widely used for adjuvant breast
cancer treatment, and cutaneous side effects are
seldom observed. This case of eruptive keloids in
association with letrozole therapy provides support
for an endocrine influence.CASE REPORT
A 77-year-old African-American woman pre-
sented to our dermatology clinic in November 2013
for evaluation of new and enlarging keloids on her
chest, neck, and back. The patient had a personal
history of keloid formation after acneiform lesions
starting in her 20s and 30s, and her father had a
history of keloids. She had infiltrating ductal
carcinoma diagnosed in June 2012 for which she
underwent a lumpectomy and external beam
radiation. One year before presenting to our clinic,
an aromatase inhibitor (letrozole 2.5 mg orally) was
added as adjuvant therapy in November 2012.Within
2 months of initiating letrozole therapy, the patient
subsequently noticed a dramatic increase in the size,
number, and frequency of her keloids. She reported
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aryland.edu.with her lesions. After 7 months of letrozole therapy,
she was switched to an alternative aromatase inhib-
itor, anastrozole, at a lower dose (1 mg orally). Upon
discontinuing letrozole, new lesions did not
develop, but she also denied any reduction or
improvement in her lesions. During examination at
our clinic, extensive flesh-colored and hyper-
pigmented, firm, smooth plaques were seen on
the neck, jawline, chest, breasts, axillae, and back
(Fig 1). One keloid was treated with cryotherapy and
intralesional steroid injections, with local flattening
of the lesion, but there was no change in her overall
condition.
The patient discontinued aromatase inhibitor
therapy and was started on tamoxifen, 20 mg daily,
in January 2014. After 4 months of tamoxifen
therapy, the patient did not develop any new
keloids, but her existing lesions failed to show any
significant improvement.DISCUSSION
Eruptive keloids are an uncommon cutaneous
pathology, and previously reported cases present
this phenomenon as a cutaneous manifestation of
systemic diseases. Connective tissue disorders
associated with eruptive keloids include
scleroderma and nephrogenic systemic fibrosis.1,2
In our patient’s case, the keloids erupted after
starting letrozole for adjuvant breast cancer therapy
and stopped progressing after this therapy was
discontinued, making this medication the most likely
causative agent.
Letrozole is a third-generation nonsteroidal
aromatase inhibitor commonly used to treat estrogenJAAD Case Reports 2015;1:112-3.
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Fig 1. Eruptive keloids associated with letrozole therapy. A, Multiple flesh-colored and
hyperpigmented, firm, smooth plaques of keloids across the chest of a 77-year-old woman.
B, Additional hyperpigmented, firm plaques present on the neck and jawline.
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women. Although rare, cutaneous side effects of
letrozole have been reported. A case of cutaneous
nodulosis associated with letrozole therapy
suggested an immunomodulatory mechanism
secondary to an altered hormonal environment.3
In our particular case of eruptive keloids, one
must also recognize the presence of an underlying
neoplasm. Breast cancer may have played a
pathogenic role by influencing profibrotic growth
factor levels. Transforming growth factor beta is
recognized as a central player in keloid pathophys-
iology, causing increased collagen proliferation and
deposition. Of note, breast and endometrial
malignancies have been associated with increased
transforming growth factor beta expression, and
eruptive keloids as a paraneoplastic syndrome
have been reported in cases of breast cancer and
endometrial carcinoma.4-7
In our patient’s case, the keloids erupted
exclusively after starting letrozole for adjuvant breast
cancer therapy. Given this timeline, we propose that
the aromatase inhibitor, letrozole, was the primary
causative agent. The hormonal alteration induced by
letrozole therapy may have influenced major
effectors of keloid pathophysiology. Specifically,
keloidal fibroblasts have shown increased androgen
binding in culture, and animal studies suggest that
aromatase inhibitors have an adverse effect on
cutaneous wound healing through a hormonally
mediated pathway.8,9 Furthermore, keloid eruption
and enlargement have been reported during times of
hormonal change such as pregnancy.10 Although theformation of keloids is unquestionably a complex
and multifactorial pathogenesis, the evident role of
endocrine factors lends support to letrozole as a
causative agent for eruptive keloids.
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